TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05599984
Drug: ABBV-706
Normalized name: ABBV-706
DrugBank: ABBV-706 (DB18710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT05599984
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05599984
Drug: Budigalimab
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT05599984
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion
Study: NCT06532591
Drug: cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-1/CTLA-4 bispecific antibody，Cadonilimab 10mg/kg IV, q3w, paclitaxel 175mg/m2 or albumin-bound paclitaxel 260mg/m2 ivgtt d1, q3w carboplatin AUC 5 ivgtt d1, q3w
Study: NCT05071053
Drug: Ramucirumab (CYRAMZA®)
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion
Study: NCT05071053
Drug: Tusamitamab ravtansine (SAR408701)
Normalized name: mirvetuximab soravtansine
DrugBank: Tusamitamab ravtansine (DB17448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion
Study: NCT06532006
Drug: HLX22
Normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HLX22 15mg/kg Q3w
Study: NCT06532006
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg q3w
Study: NCT06532006
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W
Study: NCT06532006
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m2 ,Q3W
Study: NCT06236165
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.
Study: NCT06236165
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months.
Study: NCT05476042
Drug: Erythropoietin prescription
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin 3000 units in normal saline
Study: NCT05476042
Drug: Erythropoietin prescription
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin 6000 units in normal saline
Study: NCT05937438
Drug: Immune Checkpoint Inhibitors
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year
Study: NCT06491914
Drug: Aflibercept 8 mg
Normalized name: aflibercept 8 MG in 0.07 ML Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by intravitreal (IVT) injection
Study: NCT04171622
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04943042
Drug: Avatrombopag
Normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to prescription
Study: NCT05750823
Drug: Ruxolitinib Cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream will be applied twice daily for upto 48 weeks
Study: NCT04632992
Drug: Entrectinib
Normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
Study: NCT00040625
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00040625
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05824468
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable solution
Study: NCT05824468
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsule
Study: NCT04632992
Drug: Inavolisib
Normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
Study: NCT04632992
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
Study: NCT04632992
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
Study: NCT04632992
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
Study: NCT04632992
Drug: Trastuzumab Emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
Study: NCT04632992
Drug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
Study: NCT04632992
Drug: Tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
Study: NCT04632992
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
Study: NCT04632992
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
Study: NCT04632992
Drug: Pralsetinib
Normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
Study: NCT05491200
Drug: Prasugrel based short DAPT
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus
Study: NCT05491200
Drug: Prasugrel based standard DAPT
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prasugrel based DAPT for 1 year
Study: NCT06118905
Drug: Denosumab 60 MG/ML
Normalized name: denosumab 60 MG/ML
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects to receive Denosumab 60mg SQ and Zoledronic acid placebo IV
Study: NCT04294043
Drug: Gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study subjects will receive an infusion of gallium nitrate.
Study: NCT06333041
Drug: Epidiolex
Normalized name: Epidiolex
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Epidiolex (cannabidiol) oral solution is a clear, colorless to yellow liquid containing cannabidiol at a concentration of 100 mg/mL. Inactive ingredients include dehydrated alcohol (7.9% w/v), sesame seed oil, strawberry flavor, and sucralose.
Study: NCT05275439
Drug: SL-172154
Normalized name: vitamin B12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study: NCT05275439
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy drug approved for use in MDS and AML.
Study: NCT05275439
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug approved for use in AML.
Study: NCT05846867
Drug: AK119
Normalized name: AK119
DrugBank: AK119 (DB16423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK119 IV every 2 weeks.intravenous infusion
Study: NCT05846867
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK112 IV every 2 weeks.intravenous infusion
Study: NCT05846867
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin: 85mg/m2, intravenous infusion
Study: NCT05846867
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 180mg/m2, intravenous infusion
Study: NCT05846867
Drug: Calcium folinate
Normalized name: Calcium folinate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium folinate: 400mg/m2, intravenous infusion
Study: NCT04234022
Drug: Zn-DDC
Normalized name: ZALCITABINE (DIDEOXYCYTIDINE,ddC)
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zn-DDC added to myeloma samples for culturing
Study: NCT04234022
Drug: Pomalidomide with Zn-DDC
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanalidomide with Zn-DDC added to myeloma samples for culturing
Study: NCT05133336
Drug: Saroglitazar Magnesium 1 mg
Normalized name: pitavastatin magnesium 1 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to Saroglitazar Magnesium 1 mg arm will receive Saroglitazar Magnesium 1 mg treatment for the entire treatment period up to Week 52.
Study: NCT05133336
Drug: Saroglitazar Magnesium 2 mg
Normalized name: pitavastatin magnesium 2 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to Saroglitazar Magnesium 2 mg arm are switched to Saroglitazar Magnesium 1 mg treatment up to Week 52
Study: NCT04670068
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2 IV for 3 consecutive days
Study: NCT05694624
Drug: Para Aminohippurate
Normalized name: para-aminohippurate
DrugBank: Aminohippuric acid (DB00345)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Measurements of renal plasma flow and glomerular filtration rate
Study: NCT06430437
Drug: SHR-A1811
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR-A1811 administered intravenously every 3 weeks (Q3W)
Study: NCT06430437
Drug: Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Camrelizumab administered intravenously every 3 weeks (Q3W)~Drug: Pemetrexed Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Paclitaxel Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Carboplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Cisplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)
Study: NCT06419075
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention of 50 cc TXA (2 mg/mL) local infiltration is determined after carefully reviewing the literature. Scarafoni et al. recommends that the local TXA should not exceed at a concentration of 5-10 mg/mL to avoid cytotoxicity that may affect the wound re-epithelialization (22). In a prospective study on facelift bleeding, Kochuba et al. demonstrates that local TXA (1-2 mg/mL) with total 100 mg and 200 mg TXA safely and effectively decreased bleeding, operating room time, and drain output compared with traditional local anesthetic technique (14). Fathimani et all reports the local use of modified tumescent anesthesia solution with low TXA concentration (2 mg/dL) and total average dosage of TXA ranging 120-1000 mg is safe and promising in achieving less ecchymosis, edema, and seroma in common facial cosmetic surgical procedures (31). With a total dosage of 100 mg TXA and a volume of 50 cc injection, the concentration is calculated to be 2 mg/dL.
Study: NCT06419075
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention of 50 cc Vasopressin (0.1U/mL) local infiltration is determined from several systematic reviews. Hafidh et al. shows that injection of diluted Vasopressin (3.6 to 10 units) with various concentration during hysterectomy significantly reduces the intraoperative blood loss when compared to placebo, and without increasing the hazard of cardiovascular toxicities. Cui et al. reports similar results, but including other vaginal surgeries. The common preparation for dilute Vasopressin is 0.1 U/mL or 1.0 U/mL from a 1cc vial of 20 U/mL Vasopressin. The advantage of 0.1 U/mL concentration is to avoid a relatively large bolus of concentrated 1.0 U/mL Vasopressin injected intravascularly by accident. A cumulative total dose of 4 to 6 units of Vasopressin administered in a dilute solution is proposed to be an upper limit. Therefore, the cumulative total dose of 5 units Vasopressin from 50 cc (0.1U/mL) is in the safe therapeutic range.
Study: NCT05289063
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Study: NCT05955066
Drug: Baricitinib 4 MG
Normalized name: baricitinib 4 MG
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 capsule (4mg) daily for 24 weeks
Study: NCT04793152
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration as outlined
Study: NCT06098833
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
Study: NCT06046729
Drug: Eltrekibart
Normalized name: Eltrekibart
DrugBank: Eltrekibart (DB19017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06513312
Drug: Lenacapavir Injection
Normalized name: lenacapavir Injection
DrugBank: Lenacapavir (DB15673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT06513312
Drug: Lenacapavir Tablet
Normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06513312
Drug: Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05052996
Drug: LEN
Normalized name: LENS
DrugBank: Scutellaria baicalensis root (DB14364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT06315920
Drug: Parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Single dose of 40mg of IV Parecoxib.
Study: NCT06315920
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 5 mg of IV Morphine.
Study: NCT05030675
Drug: Fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05457959
Drug: Poly ICLC
Normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IM
Study: NCT05258071
Drug: Pirepemat
Normalized name: Pirepemat
DrugBank: Pirepemat (DB19165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use
Study: NCT05645146
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be provided with a 12 week supply of nicotine patches
Study: NCT05645146
Drug: Nicotine Lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be provided with a 12 week supply of nicotine lozenges
Study: NCT06532162
Drug: 1% Lidocaine Paracervical Block
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 22-gauge spinal needle will be loaded with 10 mL of 1% lidocaine with epinephrine.~The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
Study: NCT06532162
Drug: Normal Saline Paracervical Injection
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 22-gauge spinal needle will be loaded with 10 mL of normal saline. The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
Study: NCT05721755
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05721755
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05721755
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05369975
Drug: Imlifidase
Normalized name: Imlifidase
DrugBank: Imlifidase (DB15258)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Study: NCT05745064
Drug: TL-925
Normalized name: Thallous chloride Tl 201
DrugBank: Thallous chloride Tl-201 (DB16624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TL-925 is an eye drop.
Study: NCT05936151
Drug: Retatrutide
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06570447
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Glofitamab Injection solution, after Obinutuzumab pretreatment on Day 1 of Cycle 1, patients followed a step-dose escalation regimen.
Study: NCT06570447
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide: 30 mg/d orally twice a week for 21 days as a treatment cycle.
Study: NCT06489028
Drug: allo-APZ2-CVU
Normalized name: allo-APZ2-CVU
DrugBank: Skin-derived ABCB5-positive Mesenchymal Stem cells (DB17862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
Study: NCT06444880
Drug: Ubamatamab
Normalized name: Ubamatamab
DrugBank: Ubamatamab (DB18875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT06444880
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by IV
Study: NCT04605081
Drug: Naltrexone and Bupropion (NB) medication
Normalized name: bupropion and naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NB medication will be taken daily in pill form.
Study: NCT05986422
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment period consists of six weeks of daily intake of either Methylprednisolone or placebo (depending on randomization), followed by an additional six weeks of daily intake of open-label Methylprednisolone. During the study, follow-up assessments will be conducted at two points: at week 8 and week 20 from the start of each treatment phase.